Repare Therapeutics (NASDAQ:RPTX) Posts Quarterly Earnings Results, Beats Expectations By $0.10 EPS

Repare Therapeutics (NASDAQ:RPTX) posted its earnings results on Monday. The company reported ($0.67) earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.10, Zacks reports. Repare Therapeutics had a negative net margin of 99.76% and a negative return on equity of 40.87%.

Repare Therapeutics Stock Down 1.7 %

RPTX stock opened at $1.16 on Tuesday. The company has a market cap of $49.31 million, a price-to-earnings ratio of -0.58 and a beta of 0.88. Repare Therapeutics has a 52 week low of $1.06 and a 52 week high of $7.28. The business has a fifty day simple moving average of $1.26 and a 200-day simple moving average of $2.47.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on RPTX. Lifesci Capital reiterated a “market perform” rating on shares of Repare Therapeutics in a report on Friday, December 13th. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Repare Therapeutics in a research report on Friday, November 8th. Bloom Burton lowered Repare Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 10th. Finally, Stifel Nicolaus decreased their price target on Repare Therapeutics from $9.00 to $4.00 and set a “buy” rating on the stock in a research note on Friday, December 13th.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.